Camostat

Source: Wikipedia, the free encyclopedia.
Camostat
Clinical data
Trade namesFoipan
Other namesFOY-305
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • US: Not FDA approved
  • In general: ℞ (Prescription only)
Identifiers
  • N,N-Dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate
JSmol)
  • CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
  • InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) checkY
  • Key:XASIMHXSUQUHLV-UHFFFAOYSA-N checkY
  (verify)

Camostat is a

reflux esophagitis.[1][2] The oral proteolytic enzyme inhibitor has been on the market since 1985 under the trade name Foipan Tablets. The manufacturer is Ono Pharmaceutical. The drug is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis.[3][4][5][6][7]

Pharmacology

It is an inhibitor of the enzyme transmembrane protease, serine 2 (TMPRSS2). For chronic

reflux esophagitis 300 mg are taken. The daily dose is split in 3 doses and taken after each meal.[1][8]

Side effects

As side effects allergic reactions including anaphylaxis, hypersensitivity, hyperkalemia, platelet and leukocyte depletion, liver dysfunction, jaundice have been reported.[9]

COVID-19

Camostat 100mg tablets (Japanese Blister)

Inhibition of TMPRSS2 partially blocked infection by

SARS-CoV and Human coronavirus NL63 in HeLa cell cultures.[10]
Another
SARS-CoV-2, the virus responsible for COVID-19.[11][12] It is currently in many Phase 1 and Phase 2 clinical trials.[13][14]

Camostat decreased CRP levels better compared to Lopinavir/Ritonavir in a small study of mild COVID-19 patients.[15] Camostat decreased COVID-19 severity, improved inflammatory markers and oxygenation compared to hydroxychloroquine treated patients.[16][12]

A study of 205 COVID-19 patients treated with Camostat, carried out at Aarhus University Hospital in Denmark and concluding in April 2021, showed no noticeable effects of Camostat on duration of hospitalisation or severity of the cases, but noted that higher doses (the study used 600 mg Camostat daily dosage) might still have a possible effect.[17]

On July 1, 2021, the AIDS Clinical Trials Group announced that the Camostat group on the "ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial" would not be moving forward to Phase 3. The trial demonstrated no safety concerns but also no changes in viral shedding or symptom improvement.[18]

References

  1. ^ a b "FOIPAN® Tablets 100mg" (PDF). Ono Pharmaceutical Co., Ltd.
  2. ^ "Camostat". drugs.com.
  3. PMID 11779708
    .
  4. PMID 18220789
    .
  5. S2CID 6522071
    .
  6. PMID 25666761
    .
  7. S2CID 207652863
    .
  8. PMID 33176395
    .
  9. ^ "医療用医薬品 : カモスタットメシル酸塩 (カモスタットメシル酸塩錠100mg「日医工」)". KEGG (in Japanese). Retrieved 2021-02-05.
  10. PMID 22496216
    .
  11. PMID 32142651
    .
  12. ^
    PMID 34611326
    .
  13. ^ Clinical trial number NCT04374019 for "Novel Agents for Treatment of High-risk COVID-19 Positive Patients" at ClinicalTrials.gov
  14. ^ "Search of: camostat - covid - List Results". ClinicalTrials.gov. Retrieved 2021-02-04.
  15. doi:10.1101/2020.12.10.20240689
    .
  16. PMID 33225308
    .
  17. ^ "Middel mod halsbrand bremsede ikke Covid-19". newsroom.au.dk (in Danish). Retrieved 2021-04-28.
  18. ^ "ACTG announces Camostat will not advance to phase 3 in outpatient treatment study for COVID-19". EurekAlert!. Retrieved 2021-07-01.

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Camostat&oldid=1209237581"